InSilico Medicine Cayman TopCo (HKG:3696)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
60.80
-1.60 (-2.56%)
At close: Apr 17, 2026
Market Cap34.80B
Revenue (ttm)437.73M -34.5%
Net Income-2.74B
EPS-34.87
Shares Out572.40M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,440,350
Average Volume3,549,842
Open61.30
Previous Close62.40
Day's Range59.60 - 61.85
52-Week Range29.98 - 80.90
Betan/a
RSI53.42
Earnings DateMar 30, 2026

About HKG:3696

InSilico Medicine Cayman TopCo operates as an artificial intelligence (AI)-based biotech company that helps to develop and manufacture novel drugs in Hong Kong, the United States, the United Kingdom, Mainland China, and internationally. The company develops solutions to discover and develop drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. It also offers Pharma.AI platform, a commercially end-to-end generative Al software and automation platform which is ... [Read more]

Sector Technology
Founded 2014
Employees 317
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3696
Full Company Profile

Financial Performance

In 2025, HKG:3696's revenue was $56.24 million, a decrease of -34.48% compared to the previous year's $85.83 million. Losses were -$352.32 million, 1960.8% more than in 2024.

Financial numbers in USD Financial Statements